Leerink Swann Maintains an 'Outperform' on Teva Pharma (TEVA); Review with Patent Specialist
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $37.27 -0.53%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Leerink Swann maintains an 'Outperform' on Teva Pharma (NASDAQ: TEVA) price target of $48.00.
Analyst, Jason M. Gerberry, said, "With the patent dispute likely heading to a patent trial on Nov. 7 and TEVA capturing a meaningful contribution from the sale of a generic substitute (we estimate ~4% of EPS), we decided to review the case with a MEDACorp patent specialist. Feedback from the patent specialist suggests AstraZeneca (NYSE: AZN) is likely to get a favorable ruling on Pulmicort's '603 patent, which would prevent the generic competitors from launching until 2019 and leave TEVA as the sole generic for another 7 years. While many investors are focused on bigger picture issues that may be addressed at TEVA's Investor Day (12/11), we view likely defensibility of g-Pulmicort as an incremental positive."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday.
Analyst, Jason M. Gerberry, said, "With the patent dispute likely heading to a patent trial on Nov. 7 and TEVA capturing a meaningful contribution from the sale of a generic substitute (we estimate ~4% of EPS), we decided to review the case with a MEDACorp patent specialist. Feedback from the patent specialist suggests AstraZeneca (NYSE: AZN) is likely to get a favorable ruling on Pulmicort's '603 patent, which would prevent the generic competitors from launching until 2019 and leave TEVA as the sole generic for another 7 years. While many investors are focused on bigger picture issues that may be addressed at TEVA's Investor Day (12/11), we view likely defensibility of g-Pulmicort as an incremental positive."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aurinia settles patent dispute with Teva over generic voclosporin
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
